Hidradenitis Suppurativa

Dermatology
29
Pipeline Programs
16
Companies
27
Clinical Trials
4 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
13
1
10
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1493%
Small Molecule
17%
+ 13 programs with unclassified modality

On Market (2)

Approved therapies currently available

UP
BIMZELXApproved
bimekizumab
UCB Pharma
injection2023
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002

Competitive Landscape

16 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
5 programs
1
4
1
BimekizumabPhase 3Monoclonal Antibody1 trial
BimekizumabPhase 3Monoclonal Antibody1 trial
BimekizumabPhase 3Monoclonal Antibody1 trial
BimekizumabPhase 3Monoclonal Antibody1 trial
BimekizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03248531Completed90Est. Feb 2019
NCT04901195Active Not Recruiting658Est. Jul 2026
NCT04242446Completed505Est. Feb 2023
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
1
1
1
adalimumabPhase 3Monoclonal Antibody
LutikizumabPhase 2Monoclonal Antibody1 trial
Impact of Hidradenitis Suppurativa on Quality of Life FunctionsN/A1 trial
Active Trials
NCT03288337Completed400Est. Sep 2022
NCT06524635Recruiting60Est. Feb 2027
PolyNovo
PolyNovoAustralia - Port Melbourne
1 program
1
NovoSorb® BTMPhase 41 trial
Active Trials
NCT05477225Unknown10Est. Jul 2025
MoonLake Immunotherapeutics
5 programs
1
4
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05322473Completed234Est. Aug 2023
NCT06768671Recruiting35Est. Mar 2026
NCT06411379Active Not Recruiting418Est. Jun 2026
+2 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
1
adalimumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01635764Completed508Est. Aug 2016
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
2
1
Spesolimab i.v.Phase 2/31 trial
Spesolimab - solution for infusionPhase 21 trial
Spesolimab 1200 mgPhase 21 trial
Active Trials
NCT04762277Completed52Est. Apr 2022
NCT04876391Completed45Est. Apr 2024
NCT05819398Completed209Est. Mar 2025
Avalo Therapeutics
1 program
1
AVTX-009 Regimen 1Phase 21 trial
Active Trials
NCT06603077Active Not RecruitingEst. Apr 2026
Insmed
InsmedBRIDGEWATER, NJ
1 program
1
BrensocatibPhase 21 trial
Active Trials
NCT06685835Active Not Recruiting214Est. Nov 2026
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
EltrekibartPhase 21 trial
Active Trials
NCT06046729Active Not Recruiting352Est. Aug 2026
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
FostamatinibPhase 2Small Molecule1 trial
Active Trials
NCT05040698CompletedEst. Jan 2023
InflaRx
InflaRxJENA, Germany
1 program
1
IFX-1Phase 21 trial
Active Trials
NCT03001622Completed12Est. Jul 2017
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
ImsidolimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04856930Completed149Est. Dec 2022
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
MEDI8968Phase 21 trial
Active Trials
NCT01838499Terminated224Est. Oct 2014
Sanofi
SanofiPARIS, France
1 program
1
SAR445399Phase 21 trial
Active Trials
NCT07225569Recruiting144Est. Dec 2027
Design Therapeutics
1 program
1
Injectable suspension of allogeneic adult mesenchymal stem cellsPhase 1/21 trial
Active Trials
NCT05934825UnknownEst. Oct 2025
CSL Behring
CSL BehringIL - Bradley
1 program
1
Recombinant anti-granulocyte colony-stimulating factorPhase 11 trial
Active Trials
NCT03972280Completed39Est. Oct 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
PolyNovoNovoSorb® BTM
MoonLake ImmunotherapeuticsSonelokimab
UCB PharmaBimekizumab
MoonLake ImmunotherapeuticsSonelokimab
MoonLake ImmunotherapeuticsSonelokimab
MoonLake ImmunotherapeuticsSonelokimab
UCB PharmaBimekizumab
UCB PharmaBimekizumab
UCB PharmaBimekizumab
Abbottadalimumab
Boehringer IngelheimSpesolimab i.v.
SanofiSAR445399
InsmedBrensocatib
Avalo TherapeuticsAVTX-009 Regimen 1
AbbVieLutikizumab

Showing 15 of 27 trials with date data

Clinical Trials (27)

Total enrollment: 6,164 patients across 27 trials

NCT05477225PolyNovoNovoSorb® BTM

A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions

Start: Oct 2022Est. completion: Jul 202510 patients
Phase 4Unknown

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Start: Jun 2025Est. completion: Jun 2028835 patients
Phase 3Enrolling By Invitation

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Start: Apr 2025Est. completion: May 202940 patients
Phase 3Recruiting

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Start: Dec 2024Est. completion: Mar 202635 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start: May 2024Est. completion: Jun 2026422 patients
Phase 3Active Not Recruiting

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start: May 2024Est. completion: Jun 2026418 patients
Phase 3Active Not Recruiting

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Start: May 2021Est. completion: Jul 2026658 patients
Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Start: Mar 2020Est. completion: Sep 2022509 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Start: Feb 2020Est. completion: Feb 2023505 patients
Phase 3Completed

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa

Start: Apr 2012Est. completion: Aug 2016508 patients
Phase 3Completed

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Start: Apr 2023Est. completion: Mar 2025209 patients
Phase 2/3Completed

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start: Dec 2025Est. completion: Dec 2027144 patients
Phase 2Recruiting

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Start: Dec 2024Est. completion: Nov 2026214 patients
Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

Start: Sep 2024Est. completion: Apr 2026
Phase 2Active Not Recruiting

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Start: Aug 2024Est. completion: Feb 202760 patients
Phase 2Recruiting

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start: Oct 2023Est. completion: Aug 2026352 patients
Phase 2Active Not Recruiting

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Start: Apr 2022Est. completion: Aug 2023234 patients
Phase 2Completed

Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

Start: Oct 2021Est. completion: Jan 2023
Phase 2Completed

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

Start: Aug 2021Est. completion: Apr 202445 patients
Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Start: Jul 2021Est. completion: Dec 2022149 patients
Phase 2Completed
NCT04762277Boehringer IngelheimSpesolimab - solution for infusion

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Start: Apr 2021Est. completion: Apr 202252 patients
Phase 2Completed

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Start: Sep 2017Est. completion: Feb 201990 patients
Phase 2Completed

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

Start: Dec 2016Est. completion: Jul 201712 patients
Phase 2Completed

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Start: May 2013Est. completion: Oct 2014224 patients
Phase 2Terminated
NCT05934825Design TherapeuticsInjectable suspension of allogeneic adult mesenchymal stem cells

Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa

Start: Oct 2022Est. completion: Oct 2025
Phase 1/2Unknown
NCT03972280CSL BehringRecombinant anti-granulocyte colony-stimulating factor

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Start: Jul 2019Est. completion: Oct 202239 patients
Phase 1Completed
NCT03288337AbbVieImpact of Hidradenitis Suppurativa on Quality of Life Functions

Impact of Hidradenitis Suppurativa on Quality of Life Functions

Start: Apr 2015Est. completion: Sep 2022400 patients
N/ACompleted

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

10 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 6,164 patients
Monoclonal Antibody is the dominant modality (93% of programs)
16 companies competing in this space